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ABSTRACT
Melanoma is the most dangerous and treatment-resistant skin cancer. Tumor 
resistance and recurrence are due to the persistence in the patient of aggressive cells 
with stem cell features, the cancer stem cells (CSC). Recent evidences have shown 
that CSC display a distinct metabolic profile as compared to tumor bulk population: 
a promising anti-tumor strategy is therefore to target specific metabolic pathways 
driving CSC behavior. Biguanides (metformin and phenformin) are anti-diabetic drugs 
able to perturb cellular metabolism and displaying anti-cancer activity. However, their 
ability to target the CSC compartment in melanoma is not known. Here we show that 
phenformin, but not metformin, strongly reduces melanoma cell viability, growth 
and invasion in both 2D and 3D (spheroids) models. While phenformin decreases 
melanoma CSC markers expression and the levels of the pro-survival factor MITF, 
MITF overexpression fails to prevent phenformin effects. Phenformin significantly 
reduces cell viability in melanoma by targeting both CSC (ALDHhigh) and non-CSC 
cells and by significantly reducing the number of viable cells in ALDHhigh and ALDHlow-
derived spheroids. Consistently, phenformin reduces melanoma cell viability and 
growth independently from SOX2 levels. Our results show that phenformin is able 
to affect both CSC and non-CSC melanoma cell viability and growth and suggests its 
potential use as anti-cancer therapy in melanoma.
INTRODUCTION
Melanoma is the most aggressive, highly 
metastasizing and therapy-resistant skin tumor, with 
increasing incidence in the last decades. B-RAF inhibitors 
(B-RAFi) and the recently approved immune-checkpoint 
inhibitors ipilimumab and nivolumab/pembrolizumab 
have improved the progression-free survival of metastatic 
melanoma patients, however a large number of patients 
do not respond and many display disease relapse [1–3]. 
In the last few years, the contribution of cancer stem 
cells (CSC) to drug resistance has been clarified in many 
cancer types, including breast cancer and leukemia 
[4–6]. Conventional therapies kill mainly regular tumor 
cells while sparing CSC, leading to drug resistance and 
therapeutic failure. However, in melanoma, CSC existence 
and the selectivity/specificity of markers used for CSC 
isolation have been highly questioned in the last few years 
[7]. Evidence suggests that melanoma tumor growth is 
orchestrated by subpopulations of tumor-maintaining cells 
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that can dynamically switch from a more differentiated 
state, and vice versa [8]. Nevertheless, many report also 
support the hierarchical CSC model in melanoma and 
several melanoma CSC markers have been identified so 
far, including the multi-drug resistance ABCB5 transporter 
and aldehyde dehydrogenase (ALDH) enzymes [9, 10]. 
We and others have recently shown the ability of ALDH 
activity to select for melanoma CSC [10–12]. High ALDH 
levels protect melanoma cells from apoptosis while 
ALDH1 blockade prevents tumor relapse [10–13].
It has become widely accepted that alterations of 
tumor cell metabolism are hallmarks of cancer [14, 15] 
and that targeting tumor cell metabolism is a promising 
anti-cancer strategy [16]. CSC seem to have specific 
metabolic profiles [17, 18], suggesting that targeting 
regulators of cancer cell metabolism might be a valuable 
CSC-eradicating approach. Biguanides, among which 
metformin and phenformin are the most widely known, 
are organic compounds with hypoglycaemic properties. 
Metformin is the first medication used to treat type II 
diabetes worldwide. Interestingly, biguanides display 
anti-cancer properties. Epidemiological evidences indicate 
a 30% lower risk for diabetic patients under metformin 
treatment to develop cancer [19, 20]. Our group has 
recently confirmed the anti-tumor effect of metformin and 
phenformin in breast cancer by targeting both tumor and 
microenvironment cells [21–23]. Biguanides act mainly 
by inhibiting mitochondrial oxidative phosphorylation 
(OXPHOS) through the blockade of mitochondrial 
complex-1 [24]. In melanoma cells, OXPHOS plays 
an important role in ATP production [25] and recent 
preclinical studies targeting melanoma cell mitochondrial 
bioenergetic metabolism have shown to be effective 
[26–29]. However, the effect of biguanides on melanoma 
growth and invasion is controversial. On one side, 
metformin seems to inhibit melanoma development [30, 
31] and prevent invasion and metastasis [32]. On the other 
side, metformin accelerates B-RAF mutated melanomas 
growth in vivo by sustaining angiogenesis [33]. Different 
reports have shown the ability of metformin to selectively 
kill cancer stem cells [34, 35] also by reverting their 
quiescent state [36]. As a consequence, the combination 
of metformin with chemotherapy targeting the non-stem 
like compartment of the tumor is promising [37]. Recent 
findings suggest that other biguanides affect melanoma 
cell growth [38], possibly by reducing stem cell features 
[39]. Among these, phenformin strongly reduces 
melanoma growth and when combined with the B-RAFi 
PLX4720 gives a significant therapeutic advantage. 
Although phenformin seems to target specifically slow 
cycling melanoma cells [40], the direct effect on the CSC 
compartment of this tumor is unknown.
In the present work, we investigated the ability of 
phenformin to target the CSC compartment in melanoma 
by analyzing primary and metastatic melanoma cells both 
in monolayer cell cultures and 3D spheroids. We show that 
phenformin, but not metformin, abrogates melanoma cell 
growth and invasion in 2D and 3D models and affects both 
CSC and non-CSC cells in melanoma.
RESULTS
Phenformin decreases melanoma cell viability in 
both monolayer and spheroids cell cultures
First, we tested biguanides toxicity on melanoma 
cells. Besides SK-MEL-28 and A375 cells, we included 
the primary melanoma cell line BTC#2 in the analysis as 
a representative specimen of B-RAF-mutated melanoma 
cells established from a primary aggressive melanoma 
[41]. In accordance with previous findings [37], 
phenformin reduced melanoma cell viability by MTT 
(Figure 1A, upper panel) and cell proliferation by trypan 
blue cell counting starting from 24h after stimulus up 
to 72h (Figure 1A, lower panel). Interestingly, although 
biguanides interfere with cell metabolism, we observed 
similar results between MTT, a mitochondrial metabolism-
sensitive viability assay, and trypan blue cell counting 
analyses. Since cell responses in 3D-cell cultures are 
similar to in vivo behavior [42], we also tested the effect 
of phenformin on melanoma spheroids by measuring 
cell viability by trypan blue cell counting 10 days after 
treatment. First of all, we observed a slight, but not 
significant, decrease in the number of viable cells/sphere 
over time in untreated SK-MEL-28 and BTC#2 spheroids 
(data not shown). This putatively reflects the different 
sensitivity of these cells to the microenvironmental 
conditions generated in the spheroid subcompartments, 
such as suboptimal nutrition and low oxygen supply 
[43]. When melanoma-derived spheroids were treated 
with phenformin, we observed a strong reduction in SK-
MEL-28 and BTC#2 sphere size and morphology (Figure 
1B, upper panel) as well as the number of viable cells in 
all cell lines upon treatment (Figure 1B, lower panel). 
Contrarily, the size and shape of A375-derived spheroids 
was only slightly affected by the treatment (Figure 1B). 
In line with the decrease in cell viability observed in 
monolayer cell cultures upon treatment with phenformin, 
we noticed a stronger effect of the drug on BTC#2-
derived spheroids as compared to the other melanoma cell 
lines (Figure 1B). Interestingly, treatment of melanoma 
spheroids with a lower dose of phenformin (0.5mM) for 
10 days was still able to reduce melanoma sphere-size 
(SK-MEL-28 and BTC#2) and the number of viable cells/
sphere (Supplementary Figure 1A and 1B).
As opposite to what observed for phenformin, no 
considerable effect of metformin on cell viability and 
proliferation was observed in monolayer cell cultures 
(Supplementary Figure 2A). In melanoma-derived 
spheroids, the number of viable cells/sphere at day10 
was significantly reduced by metformin in BTC#2 and 
SK-MEL-28-derived spheroids, but not in A375 ones 
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Figure 1: Phenformin reduces melanoma cell viability in both 2D and 3D models. A. Melanoma cells were seeded, treated 
with 0.1-1mM phenformin and MTT assay (upper panel) or blue trypan cell counting (lower panel) were performed up to 72h after 
treatment. B. Melanoma cells were seeded in ultralow-attachment plates in complete medium for 96h. Once formed, spheroids were 
treated with 1mM phenformin and photographed at indicated timepoints (upper panel). At day 10, spheroids were harvested, mechanically 
disaggregated and viable cells were counted by trypan blue staining. Data represent the mean ±SD of the experiment performed in triplicate 
and are represented as the % of viable cells/spheroid over untreated (NT) spheroids. Student T-test was performed for statistical analysis 
of data (* p<0.05; ** p<0.01). C. SK-MEL-28, A375 and BTC#2 cells were treated with the indicated concentrations of phenformin for 
72h, then subjected to Annexin V/7-AAD staining. The % of cells positive for both Annexin V and 7-AAD represent cells in late apoptotic 
phase, while cells annexin-V-positive and 7-AAD-negative are in early stages of apoptosis. D. Cells were treated as above, then subjected 
to flow cytometric propidium iodide staining. The % of cells in the SubG1 peak, which is indicative of apoptosis, is shown. Results are 
representative of three independent experiments and are shown as mean ± SD. Student T-test was performed for statistical analysis of data 
by comparing NT with phen-treated cells; * p<0.05.
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(Supplementary Figure 2B). Although the effect of 
phenformin and metformin in spheroids was similar in 
some cell lines (e.g. SK-MEL-28, Supplementary Figure 
1B and Supplementary Figure 2B), all together our data 
suggest that phenformin is more effective than metformin 
in reducing melanoma cell viability.
To characterize phenformin effect on melanoma cell 
death, cells were treated with 0.5 and 1 mM phenformin 
for 72h, then harvested for Annexin V/7-AAD or PI 
staining. We observed a strong and significant induction of 
early-phase apoptosis by phenformin in all cell lines. This 
effect was dose-dependent for A375 and BTC#2 cells, 
while phenformin 0.5mM showed a stronger effect than 
1mM in SK-MEL-28 cells (Figure 1C). These results were 
confirmed by PI-staining at the same timepoint (Figure 
1D) and indicate that phenformin induces apoptosis in 
melanoma cells.
Phenformin, but not metformin, abrogates 
melanoma cell invasion in 3D spheroid models
In vivo, phenformin inhibits B-RAF-mutated 
melanoma cell growth [40], however its ability to reduce 
or inhibit melanoma metastatic process has not yet been 
assessed. To determine if phenformin affects melanoma 
cell metastasis, we performed a 3D-spheroid cell invasion 
assay on melanoma-spheroids in presence or absence of 
biguanides to evaluate the cell motility. Metformin failed 
to reduce, and even promoted, cell invasion both in SK-
MEL-28 and BTC#2 derived spheroids (Figure 2A). By 
contrast, phenformin completely blocked melanoma cell 
invasion in both cell types (Figure 2A). Since phenformin 
affects melanoma cell viability and growth (Figure 1A 
and 1B), we analyzed invasion as well as cell viability in 
the same spheroid by enzymatic digestion of the physical 
bonds between the tumor cells and the extracellular matrix. 
This procedure allowed the quantification of cell viability 
in spheroids by trypan blue dye exclusion. As shown in 
Figure 2B, the ability of phenformin to decrease melanoma 
spheroids invasion is independent from phenformin-
induced decrease in cell viability. Moreover, lower doses 
of phenformin (0.5 mM) were still able to significantly 
decrease cell invasion both in SK-MEL-28 and BTC#2 
cells (Figure 2B). Similar results were observed when 
spheroids were pre-treated with phenformin for 72h and 
allowed to invade in absence of the drug, indicating that 
phenformin fails to select for invasive cells in melanoma 
spheroids. In these conditions, metformin did not impair 
melanoma cell invasion (Supplementary Figure 3). All 
together these data demonstrate that phenformin decreases 
melanoma cell invasion in 3D models.
MITF overexpression is not protective against 
phenformin inhibitory effects
In the attempt to define the molecular basis of 
phenformin inhibitory effect on melanoma cells, we 
tested whether it could affect the expression of MITF 
(Microphthalmia-associated transcription factor) that, 
besides being a melanocytic lineage-specific marker, it is 
also a pro-survival factor in melanoma [44, 45]. Indeed, 
phenformin induced a remarkable reduction of MITF 
protein and mRNA levels in all cell lines by western 
blotting and qRT-PCR (Figure 3A and 3B). To evaluate 
whether forced expression of MITF could protect from 
phenformin cytotoxic effects, we constitutively over-
expressed MITF in melanoma cells; A375 cells, expressing 
a very low basal level of MITF [46], were transfected 
with a MITF-expressing vector or with an empty vector 
and single clones were generated by antibiotic selection. 
Two clones expressing different levels of MITF were 
selected: MITF#6 (high expression level) and MITF#9 
(medium expression level) (Figure 3C). We used CTRL#3 
and CTRL#4 clones as controls. First we verified that the 
MITF overexpressed protein was functional in our system. 
We analyzed the expression of well-established MITF 
target genes (Bcl-2, cMET and PGC1-α) in MITF clones 
by real time PCR. As shown in Figure 3C (lower panel) 
MITF overexpression increases the expression of the three 
genes in a MITF-dose dependent manner, thus confirming 
that MITF is functional in transfected cells. However, 
we failed to observe any difference in cell viability after 
treatment with phenformin between CTRL and MITF-
overexpressing cells (Figure 3D), indicating that MITF 
is not sufficient to rescue phenformin cytotoxic activity 
in melanoma cells. No effect on MITF exogenous protein 
stability was observed upon treatment (Figure 3E).
Phenformin decreases stem cell traits in 
melanoma
We have recently shown that ALDHhigh cells from 
melanoma specimens and cell lines retain CSC features 
and are highly resistant to conventional therapies [10]. 
Therefore, we asked whether phenformin is able to target 
CSC in melanoma. To this aim, we isolated ALDHhigh 
and ALDHlow melanoma cells by fluorescence-activated 
cell sorting as previously shown [10]. We chose to sort 
from SK-MEL-28 and A375 cells since only 0.8 % 
of BTC#2 cells are ALDHhigh (Supplementary Figure 
4A). As expected, ALDHhigh melanoma cells express 
significantly higher levels of ALDH1A3, SOX2 and 
CD271 than ALDHlow cells by real time PCR (Figure 
4B), western blotting (SOX2/ALDH1A1, Supplementary 
Figure 4B) and FACS analysis (CD271, Supplementary 
Figure 4C). ALDHlow cells slightly overexpressed MITF, 
consistent with its role in determining the differentiation 
towards the melanocyte lineage; as opposite, MITF 
main regulator, SOX10, was equally expressed in the 
two populations (Supplementary Figure 4D). Next, we 
evaluated the behavior of sorted ALDHhigh and ALDHlow 
SK-MEL-28 (Figure 4) and A375 cells (Supplementary 
Figure 5) in 2D and 3D models. Sorted ALDHhigh 
and ALDHlow populations were seeded on ultra-low 
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Figure 2: Phenformin, but not metformin, reduces melanoma spheroids invasion. A. Melanoma cells were resuspended in 
spheroid formation ECM, seeded in a 3D culture 96-well plate and maintained up to 72 h. Then, invasion matrix was added and after gel 
formation, complete medium containing either vehicle (NT) or 10mM metformin or 1mM phenformin was added. A set of spheroids was 
maintained in absence of invasion matrix (no matrix). Invasion area at day5 was calculated by using ImageJ software. Bar graphs display 
the area of invasion of NT or treated spheroids over no matrix and are expressed as a % over NT. B. Spheroids were obtained as in A. Then, 
0.1-1mM Phen was added to each well and pictures were taken at each timepoint. At day5, invasion matrix was digested, spheroids were 
disaggregated and viable cells were counted by trypan blue cell count. Bar graphs display the ratio between invasion (area of invasion in 
NT and treated spheroids over no matrix) and cell viability (viable cells in NT and treated spheroids over no matrix). Error bars represent 
mean ±SD of three independent experiments. Student T-test was performed for statistical analysis of data (* p<0.05; ** p<0.01).
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Figure 3: MITF is not protective against phenformin in melanoma cells. A. Total cell lysates of melanoma cells treated with or 
without 0.5-1mM phenformin up to 48h were immune-blotted with anti-human MITF antibody. B. mRNA was extracted from the same cells 
as in A and MITF expression by real-time PCR was assessed. C. Two MITF overexpressing-A375 clones (MITF#6 and 9) and two control 
clones (CTRL#3 and 4) were lysed either for MITF expression by western blotting (upper panel) or for cMET, Bcl-2 and PGC1α mRNA 
analysis by Real Time PCR (lower panel). D. MITF#6, #9, CTRL#3, #4 cell clones were seeded and treated with 0.5-1mM phenformin. 
Trypan blue cell count at 72h was performed and the number of viable cells/well is shown. Data are the mean ±SD of the experiment 
performed in triplicate. Student T-test was performed for statistical analysis of data (* p<0.05; ** p<0.01). E. Total cell lysates of MITF#6 
and #9 clones treated with or without 0.5-1mM phenformin for 48h were harvested and immunoblotted for MITF expression. Western 
blottings are representative of an experiment performed in triplicate (three biological replicates). β-actin was used as loading control.
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attachment plates to form spheroids, then monitored up 
to 14 days post-seeding. Both ALDHhigh, ALDHlow and 
bulk (unsorted) cells were able to form spheroids in these 
conditions, yet ALDHhigh cells generated slightly larger 
spheroids as compared to ALDHlow ones (Figure 4C and 
Supplementary Figure 5A, left panels). At day 14, total 
cell output of ALDHhigh-derived spheroids was similar 
to that of ALDHlow ones (Figure 4C and Supplementary 
Figure 5A, right panels). In accordance, the number of 
viable cells was not significantly different in ALDHhigh 
derived spheroids as compared to ALDHlow derived ones, 
as shown by trypan blue cell counting (Figure 4C and 
Supplementary Figure 5A, right panels). When melanoma 
cells grown as monolayer were compared with spheroids 
for ALDH activity, we observed a significant increase 
in the number of ALDHhigh cells in 3D cell cultures as 
compared to monolayer cell cultures. This suggests that 
melanoma cells grown as spheroids may increase the CSC 
compartment by upregulating ALDH activity (Figure 4D), 
however further experiments are needed to clarify this 
point. We also observed a strong variation of ALDHhigh cell 
number in melanoma 2D cell cultures over time (Figure 
4D). Although we don't have a full explanation on these 
results, it is possible that ALDH levels fluctuate in culture 
also in response to progressive metabolic changes that take 
place during the different phases of the cell cycle and as a 
function of cell density [47, 48].
In order to assess phenformin effects on the CSC 
compartment in melanoma, we isolated ALDHhigh and 
ALDHlow melanoma cells by fluorescence activated 
cell sorting and analyzed them in 2D and 3D models in 
presence or absence of phenformin. In monolayer cell 
cultures, phenformin reduced ALDH isoforms expression 
in melanoma cells (Figure 5A) and ALDHhigh and ALDHlow 
melanoma cells viability at 48h, with no significant 
difference between the two populations (Figure 5B 
and Supplementary Figure 5B). When seeded to form 
spheroids, both ALDHhigh and ALDHlow 96h-old spheroids 
were visibly similarly sensitive to phenformin at day 10 
post-treatment (Figure 5B, 5C and Supplementary Figure 
5B, 5C). This was confirmed by the evaluation of total 
cell output/spheroid (Figure 5D and Supplementary Figure 
5D) at the same timepoint, showing that phenformin 
leads to a comparable decrease in the overall number of 
cells in ALDHhigh and ALDHlow-derived spheroids. In our 
previous work, we have shown that ALDHhigh melanoma 
cells are resistant to paclitaxel, a drug currently employed 
in the treatment of advanced-stage melanoma patients 
[10]. Here we observed that while ALDHhigh cells were 
resistant to paclitaxel (Supplementary Figure 4E), 
phenformin was effective in targeting both ALDHhigh and 
ALDHlow melanoma cells. We then wanted to confirm 
these results by assessing the effect of phenformin in a 
cellular model of melanoma that overexpresses the widely 
known stem cell marker SOX2. SOX2 is a transcription 
factor essential for maintaining the tumorigenic ability 
of CSC in different tumor types [49–51]. In melanoma, 
it promotes survival and self-renewal of CSC expressing 
high levels of ALDH [49]. qPCR (Figure 6A) and western 
blotting (Supplementary Figure 6A) analyses show that 
phenformin induces a significant down-regulation of 
SOX2 in both A375 and SK-MEL-28 cells. To evaluate 
whether forced expression of SOX2 could protect from 
phenformin cytotoxic effects, we transfected A375 cells 
with a SOX2-expressing vector or with an empty vector 
as control. Single clones were generated by antibiotic 
selection; SOX2 overexpression was confirmed by western 
blotting (Figure 6B) and immuno-fluorescence (Figure 
6C and Supplementary Figure 6B). One representative 
A375-SOX2 clone (in which 100% cells overexpressed 
SOX2, Figure 6C) and one A375-CTRL clone were used. 
Phenformin strongly reduced the number of viable cells at 
72h without any difference between SOX2-overexpressing 
and CTRL clone (Figure 6D). This was confirmed by 
viability assays, MTT and trypan blue cell counting, as 
shown in Figure 6E and 6F respectively. Interestingly, 
when we assessed the levels of ectopic SOX2 in SOX2-
overexpressing cells treated with phenformin, we observed 
a strong decrease of SOX2 levels. This observation 
indicates that phenformin inhibits SOX2 expression 
through mechanisms that affect both its mRNA and 
protein.
DISCUSSION
This study shows that modulation of melanoma 
cells energetic metabolism by the OXPHOS-inhibitor 
phenformin reduces melanoma cell viability, growth 
and invasion both in monolayer cell cultures and in 
multi-cellular spheroids. We show for the first time that 
phenformin reduces stem cell features in melanoma by 
downregulating ALDH and SOX2 expression levels. 
Phenformin suppresses both CSC and non-CSC cell 
viability and growth. By contrast metformin, a phenformin 
analogue, is less effective in reducing melanoma cell 
viability and fails to decrease cell invasion.
Using both 2D- and 3D-models we observed some 
discordant results in terms of drug responses [52, 53, 
26], possibly due to different metabolic environments 
characterizing the two models. Contrarily to what observed 
in 2D-cell cultures, the metabolic activity of tumor cells 
is not homogeneous in spheroids and differs in the inner 
(glycolytic) vs outer (OXPHOS-dependent) layers of 
the spheroid structure. Since 3D cell culture approaches 
more accurately recapitulate solid tumor architecture, 
heterogeneity, differentiation and metabolism, the choice 
to use both 2D and 3D models in this study is of note 
and helps to overcome some methodological limitations 
of conventional 2D cell culture.
Phenformin, which is 50 fold more potent [54] and 
displays greater tissue bioavailability than metformin [55], 
markedly decreased melanoma cell viability by inducing 
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Figure 4: ALDHhigh melanoma cells behavior in 2D vs 3D cell culture models. A. Representative Aldefluor analysis in SK-
MEL-28 cells. Control cells incubated with Aldefluor inhibitor (DEAB) were used to identify ALDHhigh and ALDHlow cells. Purity of sorted 
populations was checked. B. Just sorted ALDHhigh, ALDHlow and bulk (total, TOT) cells were immediately lysed for mRNA analysis by 
real-time PCR for the expression of CSC markers. Data are the mean ±SD of the experiment performed in triplicate. Student T-test was 
performed for statistical analysis of data (* p<0.05; ** p<0.01). C. Sorted ALDHhigh and ALDHlow cells were seeded in complete medium 
in order to form spheroids and photographed at different timepoints. At day 14, spheroids were mechanically disaggregated and viable 
cells were counted by trypan blue. Bar graphs display total cell outputs (viable+dead cells) per spheroid (right, upper graph) or the cell 
number/sphere (right, lower graph). D. A375 and SK-MEL-28 cells were seeded at the same density in normal (monolayer) and ultralow-
attach (for spheroids) plates in complete medium. Cells were harvested up to 72h and analyzed with Aldefluor by FACS analysis. The % 
of ALDHhighcells at the different timepoints in the two cell culture conditions is shown. Error bars represent mean ±SD of five independent 
experiments. Student T-test was performed for statistical analysis of data (* p<0.05; ** p<0.01; n.s. not significative).
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Figure 5: Phenformin targets both ALDHhigh (CSC) and ALDHlow (non-CSC) melanoma cells. A. mRNA was extracted 
from melanoma cells treated with or without 0.5-1mM phenformin up to 72h. Then, ALDH1A isoforms expression by real-time PCR 
was assessed. We chose to measure ALDH1A3 and ALDH1A1 levels for A375 and SK-MEL-28 cells respectively as they are the most 
expressed ALDH isoforms in each cell type (data not shown). B. Sorted ALDHhigh and ALDHlow SK-MEL-28 cells were seeded in complete 
medium on 96-wells plates and treated with 0.5-1 mM phenformin. Cell viability at 48h was measured by trypan blue cell count. C. Sorted 
ALDHhigh and ALDHlow SK-MEL-28 cells were seeded in complete medium on ultralow-attach plates and treated with 1mM phenformin up 
to 10 days. Photographs of treated spheroids were taken at different timepoints. D. At day 10, spheroids were mechanically disaggregated 
and viable and dead cells were counted by trypan blue. Bar graphs display total cell outputs (viable+dead cells) per spheroid. Error bars 
represent mean ±SD of three independent experiments. Student T-test was performed for statistical analysis of data (* p<0.05; ** p<0.01).
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Figure 6: SOX2 overexpression in melanoma is not protective against phenformin. A. SOX2 expression was assessed by 
real-time PCR in A375 and SK-MEL-28 cells treated with or without 0.5-1mM phenformin up to 72h. B. SOX2 overexpressing-A375 
clone and a control clone were lysed for SOX2 expression by western blotting using an anti-flag antibody. C. Immunofluorescence was 
performed on A375-SOX2 clones by using anti-flag antibody (green) and dapi for nuclear staining (blue). The selected clone contains 100% 
flag-positive cells (scale bar: 25μm). D. Representative pictures of SOX2 and CTRL clones treated with or without 1mM phenformin at 72h 
(scale bar: 25μm). E. A375-CTRL and -SOX2 cell clones were seeded and treated with 0.5-1mM phenformin. MTT assay up to 72h was 
performed and cell viability is shown at each timepoint (o.d. optical density; ** p<0.01). F. Trypan blue cell count up to 72h was performed 
on the same cells as in D. The number of viable cells is shown at each timepoint. Data are the mean ±SD of the experiment performed in 
triplicate. Student T-test was performed for statistical analysis of data (* p<0.05). G. Total cell lysates of A375-SOX2 clone treated with or 
without 1mM phenformin were harvested up to 72h and immune-blotted for SOX2 expression using an anti-flag antibody. Western blottings 
are representative of an experiment performed in triplicate. β-actin was used as loading control.
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apoptosis. Further, it reduced cell growth and invasion 
in both 2D and 3D models. This fits with what observed 
on tumor growth by Yuan and colleagues in vivo [40]. 
Interestingly, we also observed marked cytotoxic effects 
induced by phenformin on melanoma cells at doses lower 
than 1mM. Since high doses phenformin are toxic in 
vivo, our data as well as observations from other groups 
support its use in the clinic at lower, more tolerable doses, 
possibly in therapeutic combination regimens [27, 40, 
51]. In addition, we observed for the first time a strong 
effect of phenformin on melanoma cell invasion thus 
indicating a potential phenformin anti-metastatic effect. 
Of note, phenformin activity on slow cycling BTC#2 cells 
is stronger as compared to fast growing cell lines. This 
is in line with the evidence that slow cycling, OXPHOS-
dependent cells are more sensitive to drugs able to disrupt 
the mitochondrial respiration chain [26]. Consistently, 
phenformin seems to target slow cycling, JARID1B-high, 
melanoma cells [40].
In melanoma, MITF is both a pro-survival and a 
differentiating factor [57]. Interestingly, MITF drives 
metabolic reprogramming of melanoma cells towards 
mitochondrial metabolism by promoting the transcription 
of several genes involved in OXPHOS [58]. In line with 
this evidence, we observed that phenformin treatment 
strongly repressed MITF endogenous expression in A375 
cells. This observation seems to indicate that phenformin 
has a transcriptional effect on MITF expression and 
suggests that MITF repression may be functional to 
phenformin activity in melanoma. However, when we 
tested the effect of phenformin in MITF-overexpressing 
melanoma cells, we did not observe any difference in drug 
response in MITF- and CTRL-cells. This seems to indicate 
that MITF is not sufficient to rescue phenformin cytotoxic 
effects in melanoma.
Melanoma is highly resistant to conventional 
treatments: even recently developed drugs show 
some degree of recurrence, this being mainly due to 
CSC persistence. Given melanoma heterogeneity and 
melanoma cell plasticity, the identification of a unique 
marker able to select cells with CSC features has been 
challenging [59]. We have previously shown that ALDHhigh 
cells in melanoma retain a CSC phenotype and recently, 
a role for SOX2 in sustaining the tumorigenic ability of 
ALDHhigh melanoma cells has been demonstrated [49]. 
Since SOX2 overexpression increases the self renewal 
ability of melanoma cells thus generating stem-like 
cells, we used this model as well as sorted ALDHhigh/low 
cells to study the effect of phenformin on the stem cell 
compartment in melanoma. We herein show for the first 
time that phenformin is among the few anti-cancer drugs 
able to target cells with the ALDHhigh CSC phenotype, 
although not specifically. Interestingly, the strong 
activity of phenformin on melanoma spheroids, which 
in turn display a higher ALDH activity as compared 
to monolayer cell cultures [60] (Figure 4D), seems to 
suggest that phenformin may have a preferential stronger 
cytotoxic effect on melanoma CSC. However, although 
ALDHhigh cells are resistant to paclitaxel, their sensitivity 
to phenformin is comparable with that of ALDHlow 
counterpart. This evidence is likely due to still unraveled 
molecular mechanisms activated by phenformin that might 
be shared by ALDHhigh and ALDHlow cells. Although we 
did not analyze glucose metabolism in melanoma CSC, it 
is reported that CSC often overexpress genes associated 
with glucose uptake, OXPHOS and fatty acid beta-
oxidation [61], explaining, at least in part, the sensitivity 
of CSC to OXPHOS inhibitors.
Modulation of cell metabolism by inhibition of 
mitochondrial complex-1 has shown promising results 
[62]. In addition, resistance to single and combinatorial 
therapies is often associated with upregulation of 
OXPHOS [16]. Given the ability of the OXPHOS-
inhibitor phenformin to target both CSC and non-CSC, 
our data provide evidence that phenformin might be a 
successful therapeutic option in melanoma, possibly in 
combination regimens.
MATERIALS AND METHODS
Reagents
Metformin (1,1-dimethylbiguanide hydrochloride), 
phenformin (N-(2-Phenylethyl)imidodicarbonimidic 
diamide monohydrochloride) and 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium bromide were purchased 
from Sigma–Aldrich (St Louis, MO). Lipofectamine 2000 
was purchased from Invitrogen (Eugene, OR). Paclitaxel 
was purchased from Accord Healthcare Italia.
Cell cultures
Human B-RAFV600E mutant melanoma cell line 
A375 was purchased from ATCC. SK-MEL-28 were a 
kind gift from Prof. Pincelli at the University of Modena 
and Reggio Emilia, Italy. Cell lines were authenticated 
by short tandem repeat DNA profiling after purchase. 
BTC#2 is a short-term melanoma cell line derived from a 
B-RAFVE600E mutated primary melanoma patient enrolled 
at Arcispedale S. Maria Nuova after signing an informed 
consent. Once isolated, BTC#2 cells were maintained in 
RPMI medium supplemented with 10% (vol/vol) heat 
inactivated fetal bovine serum (FBS). Expression of 
MART-1 by immuno-cytochemistry was used to confirm 
the identity of melanoma cells which were 98-100% 
positive. A375 and SK-MEL-28 cells were cultured in 
DMEM medium supplemented with 10% (vol/vol) FBS 
or BME medium supplemented with 10% (vol/vol) FBS 
containing penicillin/streptomycin, sodium pyruvate (1 
mM), sodium bicarbonate (1.5 g/L) and NEAA (0.1mM), 
Oncotarget6925www.impactjournals.com/oncotarget
respectively. All cell lines were incubated at 37°C under 
5% CO2. For SOX2 and MITF stable clones derivation 
see supplementary M&M.
Spheroid formation
We cultured melanoma cells either on flat bottom 
plates (2D-cell culture models) or round bottom ultra-
low attach plates (3D-cell culture models/spheroids) in 
complete cell culture media. Culturing cells in ultra-low 
attachment plates permits growth of multi-cellular tumor 
spheroids that are organotypic models of solid tumor 
tissues. Melanoma cells were harvested from monolayer 
cultures, counted and resuspended into complete medium. 
3000-4000 cells were seeded into each well of 96-well 
Corning Ultra-Low Attachment Plates (Thermo Fisher 
Scientific Inc., Waltham, MA) for 96h. Once formed, 
spheroids were incubated with vehicle or metformin/
phenformin at the indicated doses up to 10 days. The 
stimuli were renewed every 3 days. At each timepoint, 
spheroids were harvested and single cell suspension was 
obtained by mechanical disaggregation procedure for 
further analyses.
Aldefluor assay and flow cytometry
The Aldefluor kit (Stem Cell Technologies, 
Vancouver, Canada) was used to isolate or quantify cells 
with high ALDH activity. For the isolation of ALDHhigh/
low populations in melanoma, only SK-MEL-28 cells 
were used. For the quantification of ALDH activity in 
monolayer vs 3D cell cultures, A375, SK-MEL-28 and 
BTC#2-derived spheroids and monolayer cell cultures 
were analyzed at the indicated timepoints. Details on 
the sorting strategy and protocol are reported in the 
supplementary M&M section.
3D spheroid BME cell invasion assay
3D Spheroid BME Cell Invasion Assay was 
performed on SK-MEL-28 and BTC#2-derived spheroids, 
following manufacturer instructions (Trevigen 3-D 
spheroid Cell Invasion Assay, Trevigen, Gaithersburg, MD 
USA). We evaluated the ability of biguanides to inhibit 
spheroid invasion by drug-treating spheroids in invasion-
permissive conditions (method I), or by pre-treating 
spheroids before embedding them into invasion-matrix 
(method II). The two methods are described in detail in 
the supplementary M&M section.
Immuno-fluorescence
A375-SOX2 and CTRL clones were grown on 
chambers-slides for 48 hours, then washed in PBS and 
fixed in situ with buffered para-formaldehyde (4%) for 20 
minutes at RT. Cells were permeabilized with 0.1% Triton 
X-100 for 5 minutes on ice, incubated with 2% bovine 
serum albumin/10% goat serum for 20 minutes, then for 
60 minutes at 37°C with the mouse monoclonal anti-flag 
antibody (1:200, Thermo Scientific) or with FBS buffer 
alone as control. After three washes in PBS, cells were 
incubated for 60 minutes with the FITC-conjugated anti-
mouse secondary antibody (Invitrogen) at 1:1000 dilution. 
Sections were then counterstained with Dapi (1:1000 
diluted in PBS) for 5 minutes at room temperature and 
coverslipped with SlowFade® (Invitrogen) reagent.
Statistical analyses
Statistical analysis was performed by Student’s 
t-test. One or two asterisks indicate a significant 
difference, * 0.01 < P < 0.05 and ** P < 0.01, respectively.
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